Philips Advances MR Radiotherapy Imaging and Simulation for Head and Neck Cancers

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation. The company's artificial intelligence (AI) enabled MRCAT Head and Neck radiotherapy application, which allows the use of MR as the sole or primary imaging modality for radiotherapy planning in the treatment of soft tissue tumors in the head and neck, along with the brain, pelvis and prostate, has received FDA 510(k) clearance and is commercially available in the U.S.

As a result of a recent development partnership with patient-positioning company MacroMedics, Philips has also announced compatibility of MacroMedics' latest DSPS (Double Shell Positioning System) ProminentTM positioning system [1] with Philips MR Head Neck Coil. This unique solution combines the superior soft tissue imaging capabilities and the high-resolution image quality of Philips' head and neck coil with the comfort-enhancing and positional accuracy and stability features of MacroMedics' mask. These developments aim to improve the accuracy of radiotherapy planning and simulation to help achieve better patient outcomes, enhance patient comfort, and offer the efficiency benefits of an MR-only workflow.

"With this innovative mask that fits into Philips' head coil, we expect to acquire head and neck images for radiotherapy planning with diagnostic image quality and improved patient comfort," said Marielle Philippens, Associate Professor, MRI for Radiotherapy at University Medical Center Utrecht (Utrecht, The Netherlands), who is currently using the integrated Philips and MacroMedics solution.

"The superior soft tissue imaging of MR together with advances in the integration and orchestration of data, including the use of artificial intelligence, promise greater clarity and less subjectivity in planning radiotherapy for head and neck cancer," said Ilya Gipp, Chief Medical Officer Oncology Solutions at Philips. "Our collaboration with MacroMedics to develop a patient-friendly mask system compatible with our high-resolution dStream imaging coils highlights Philips’ commitment to providing the precision tools needed for the localization and characterization of difficult-to-treat tumors."

Philips' radiation oncology portfolio is designed to provide greater clarity by empowering oncologists with accurate image guidance, integrated workflows, and the versatility to deliver the precise, adaptive, personalized treatment every patient deserves. The company's products and services are enhanced through strategic clinical and technology partnerships, vendor-neutral device integration, advanced imaging and AI algorithms to help physicians deliver more confident diagnoses and treatment pathways for patients.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries.

1. Pending FDA 510 (k) clearance; not for sale in the U.S.

Most Popular Now

AI Tool Helps Predict Relapse of Pediatr…

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers. AI-assisted interpretation of brain scans may help improve...

Detecting Lung Cancer 4 Months Earlier a…

GPs may soon be able to identify patients with an increased risk of lung cancer up to 4 months earlier than is currently the case. The GP should be able...

Infectious Disease Surveillance Platform…

The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate...

Children's Health Ireland to Transf…

Healthcare teams responsible for paediatric care in Ireland are to save significant time in accessing important diagnostic imaging and reports, with the help of a new agreement with medical imaging...

NHS, Councils, and Housing could Share N…

A new technology partnership formally announced, could help NHS, local government, and housing organisations collaborate to create an unprecedented understanding of the risks and needs of people in their care...

AI-Powered Analysis of Stent Healing

Each year, more than three million people worldwide are treated with stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after implantation remains a...

Right Patient, Right Dose, Right Time

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin...

An AI Tool Grounded in Evidence-Based Me…

A powerful clinical artificial intelligence tool developed by University at Buffalo biomedical informatics researchers has demonstrated remarkable accuracy on all three parts of the United States Medical Licensing Exam (Step...

AXREM and BHTA Name Highland as 'Fu…

Hosted by trade associations AXREM and the British Healthcare Trades Association (BHTA), 'The Future of MedTech - Innovating for Tomorrow', will allow delegates to engage with speakers from the government...